Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 13, 2016

Areva Med begins lead-212 production in US

Areva Med has commenced lead-212 production at its new domestic distribution and purification unit (DDPU) in Plano, Texas.

Areva Med

Areva Med has commenced lead-212 production at its new domestic distribution and purification unit (DDPU) in Plano, Texas.

The lead-212 is a rare metal used in targeted alpha therapy (TAT), in an increasing number of studies to target cancer cells, while limiting the impact on nearby healthy cells.

Areva Med said that it has developed a unique process to extract lead-212.

With increased production capacities, Areva Med will accelerate the development of TATs using lead-212 to combat cancer.

The new facility will allow Areva Med to expand the range and increase the quality of products and services for its American partners and customers.

Areva Med CEO Patrick Bourdet said: "Our new modular and unique US plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent."

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Construction on the facility commenced in September last year.

The DDPU will house the company’s US activities in a centralised modular plant, which will also hold Areva Med subsidiary Macrocyclics’ operations.

Macrocyclics is involved in the design and manufacturing of chelating agents for nuclear medicine.

"Our new modular and unique US plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent."

Plano Mayor Harry LaRosiliere said: "It is always a great day when we can welcome to the City of Plano a US Headquarters and international company such as Areva Med, which does invaluable work in the field of cancer research.

"We look forward to their success and future expansion as they continue to develop innovative cancer therapies."

The company already operates its first-of-a-kind high-purity lead-212 production facility in France since 2013.

Areva Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform.


Image: Plano Mayor Harry LaRosiliere and Areva Med CEO Patrick Bourdet inaugurate second lead-212 production facility. Photo: courtesy of Jim Herndon.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU